A longevity biotech has dosed its first human with an experimental gene therapy aimed at reversing age-related vision loss. Early animal studies restored vision, and the first FDA-authorized trial will now test the treatment’s safety in patients. 👁️🔬🚀
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.
